This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Livant, D. L. Articles by Upadhyaya, A. Search for Related Content PubMed PubMed Citation Articles by Livant, D. L. Articles by Upadhyaya, A.

Anti-invasive, Antitumorigenic, and Antimetastatic Activities of the PHSCN Sequence in Prostate Carcinoma¹

Departments of Cell and Developmental Biology [D. L. L., R. K. B., S. M., A. U.], Surgery and Internal Medicine [K. J. P.], and Human Genetics [D. L. A., K. K.], University of Michigan Medical School, Ann Arbor, Michigan 48109-0616

Using naturally serum-free SU-ECM basement membranes as invasion substrates showed that plasma fibronectin was necessary to stimulate invasion by DU 145 human and metastatic MATLyLu (MLL) rat prostate carcinoma cells. This activity mapped to the PHSRN sequence, which induced invasion through 5ß1 integrin. PHSCN, a competitive inhibitor, blocked both PHSRN- and serum-induced invasion. Acetylated, amidated PHSCN (Ac-PHSCN-NH₂) was 30-fold more potent; however, Ac-HSPNC-NH₂ was inactive. Rats receiving injections s.c. with 100,000 MLL cells were treated systemically by i.v. injection three times weekly with 1 mg of either Ac-PHSCN-NH₂ or Ac-HSPNC-NH₂ beginning 24 h later, three times weekly with 1 mg of Ac-PHSCN-NH₂ beginning only after surgery to remove large (2 cm) MLL tumors, or were left untreated. MLL tumors grew rapidly in Ac-HSPNC-NH₂-treated and in untreated rats. MLL tumor growth in rats treated with Ac-PHSCN-NH₂ beginning 1 day after MLL cell injection was reduced by 99.9% during the first 16 days of treatment, although subsequent tumor growth occurred. MLL tumor cryosections immunostained with anti-PECAM-1 showed that Ac-PHSCN-NH₂ inhibited neovascularization by 12-fold during this time. Whether initiated after MLL cell injection or only after MLL tumor removal, Ac-PHSCN-NH₂ treatment reduced the numbers of MLL lung colonies and micrometastases by 40- to >100-fold, whereas Ac-HSPNC-NH₂ was inactive. Thus, Ac-PHSCN-NH₂ may be a potent antitumorigenic and antimetastatic agent for postsurgical use prior to extensive metastasis.

This article has been cited by other articles:

				K. Sawada, A. K. Mitra, A. R. Radjabi, V. Bhaskar, E. O. Kistner, M. Tretiakova, S. Jagadeeswaran, A. Montag, A. Becker, H. A. Kenny, et al. Loss of E-Cadherin Promotes Ovarian Cancer Metastasis via {alpha}5-Integrin, which Is a Therapeutic Target Cancer Res., April 1, 2008; 68(7): 2329 - 2339. [Abstract] [Full Text] [PDF]

				F. Donate, G. C. Parry, Y. Shaked, H. Hensley, X. Guan, I. Beck, Z. Tel-Tsur, M. L. Plunkett, M. Manuia, D. E. Shaw, et al. Pharmacology of the Novel Antiangiogenic Peptide ATN-161 (Ac-PHSCN-NH2): Observation of a U-Shaped Dose-Response Curve in Several Preclinical Models of Angiogenesis and Tumor Growth Clin. Cancer Res., April 1, 2008; 14(7): 2137 - 2144. [Abstract] [Full Text] [PDF]

				P. Khalili, A. Arakelian, G. Chen, M. L. Plunkett, I. Beck, G. C. Parry, F. Donate, D. E. Shaw, A. P. Mazar, and S. A. Rabbani A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol. Cancer Ther., September 1, 2006; 5(9): 2271 - 2280. [Abstract] [Full Text] [PDF]

				Z.-Z. Zeng, Y. Jia, N. J. Hahn, S. M. Markwart, K. F. Rockwood, and D. L. Livant Role of Focal Adhesion Kinase and Phosphatidylinositol 3'-Kinase in Integrin Fibronectin Receptor-Mediated, Matrix Metalloproteinase-1-Dependent Invasion by Metastatic Prostate Cancer Cells Cancer Res., August 15, 2006; 66(16): 8091 - 8099. [Abstract] [Full Text] [PDF]

				A. Maglott, P. Bartik, S. Cosgun, P. Klotz, P. Ronde, G. Fuhrmann, K. Takeda, S. Martin, and M. Dontenwill The Small {alpha}5{beta}1 Integrin Antagonist, SJ749, Reduces Proliferation and Clonogenicity of Human Astrocytoma Cells. Cancer Res., June 15, 2006; 66(12): 6002 - 6007. [Abstract] [Full Text] [PDF]

				A. Abdollahi, D. W. Griggs, H. Zieher, A. Roth, K. E. Lipson, R. Saffrich, H.-J. Grone, D. E. Hallahan, R. A. Reisfeld, J. Debus, et al. Inhibition of {alpha}v{beta}3 Integrin Survival Signaling Enhances Antiangiogenic and Antitumor Effects of Radiotherapy Clin. Cancer Res., September 1, 2005; 11(17): 6270 - 6279. [Abstract] [Full Text] [PDF]

				Y. Jia, Z.-Z. Zeng, S. M. Markwart, K. F. Rockwood, K. M. W. Ignatoski, S. P. Ethier, and D. L. Livant Integrin Fibronectin Receptors in Matrix Metalloproteinase-1-Dependent Invasion by Breast Cancer and Mammary Epithelial Cells Cancer Res., December 1, 2004; 64(23): 8674 - 8681. [Abstract] [Full Text] [PDF]

				C. G. Kleer, Q. Cao, S. Varambally, R. Shen, I. Ota, S. A. Tomlins, D. Ghosh, R. G. A. B. Sewalt, A. P. Otte, D. F. Hayes, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells PNAS, September 30, 2003; 100(20): 11606 - 11611. [Abstract] [Full Text] [PDF]

				E. S. White, D. L. Livant, S. Markwart, and D. A. Arenberg Monocyte-Fibronectin Interactions, Via {alpha}5{beta}1 Integrin, Induce Expression of CXC Chemokine-Dependent Angiogenic Activity J. Immunol., November 1, 2001; 167(9): 5362 - 5366. [Abstract] [Full Text] [PDF]

				C. R. Cooper, L. McLean, M. Walsh, J. Taylor, S. Hayasaka, J. Bhatia, and K. J. Pienta Preferential Adhesion of Prostate Cancer Cells to Bone Is Mediated by Binding to Bone Marrow Endothelial Cells as Compared to Extracellular Matrix Components in Vitro Clin. Cancer Res., December 1, 2000; 6(12): 4839 - 4847. [Abstract] [Full Text]